Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
Joint Authors
Zhang, Xiang
Zhang, Xueming
Wang, Saihua
Luo, Jun
Zhao, Zhihong
Zheng, Changzhu
Shen, Jieyan
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-03-26
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Background.
Pulmonary hypertension due to left ventricular heart failure with preserved ejection fraction (PH-HFpEF) is an increasingly medical problem.
The aim of the study was to evaluate the clinical efficacy of fasudil on PH-HFpEF elderly patients and to figure out the subtype of PH-HFpEF which may be the therapeutic object of fasudil.
Method.
58 PH-HFpEF elderly patients were enrolled.
Patients were diagnosed with passive pulmonary hypertension (PPH) or reactive pulmonary hypertension (RPH) by right heart catheterization and all receiving Rho kinase inhibitor fasudil for 2 weeks.
The endpoint includes changes in SpO2, NT-pro BNP, cardiac functional classification, and echocardiography measurements after 2 weeks treatment.
Results.
The course of disease in the RPH group was longer than the PPH group (p<0.05).
Cardiac output was found to be worse in the RPH group than the PPH group (p<0.01).
Besides, the RPH group demonstrated a greater transpulmonary pressure gradient (TPG) and pulmonary vascular resistance (PVR) than the PPH group (p<0.01 for both) as well as pulmonary arterial systolic pressure (PASP) and mean pulmonary arterial pressure (mPAP) (p<0.01 for both), which fits the feature of RPH.
After treatment of fasudil, in RPH group, PASP significantly decreased (p<0.01) with decreased E/E′ and increased E/A (p<0.05 for both), indicating that pulmonary haemodynamics and cardiac diastolic function were ameliorated, but the measurements in the PPH group had no significant changes.
NT-pro BNP and 6 MWD of both groups were improved (p<0.05).
The total effective rate of the RPH group was 74.29%, which was higher than 47.83% of the PPH group (p<0.05).
Conclusion.
The Rho kinase inhibitor fasudil can improve pulmonary and left ventricular haemodynamics in patients with PH-HFpEF.
The total effective rate was higher in the RPH group.
Fasudil may be a promising targeted drug for the RPH in PH-HFpEF patients.
This trial is registered with ChiCTR-INR-16009511.
American Psychological Association (APA)
Zhang, Xiang& Zhang, Xueming& Wang, Saihua& Luo, Jun& Zhao, Zhihong& Zheng, Changzhu…[et al.]. 2018. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. Canadian Respiratory Journal،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1151759
Modern Language Association (MLA)
Zhang, Xiang…[et al.]. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. Canadian Respiratory Journal No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1151759
American Medical Association (AMA)
Zhang, Xiang& Zhang, Xueming& Wang, Saihua& Luo, Jun& Zhao, Zhihong& Zheng, Changzhu…[et al.]. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. Canadian Respiratory Journal. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1151759
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1151759